Clinical trial Recruiting at 1 site Observational Ages 18 to 50

Analyzing immune responses to COVID-2019 vaccination using single-cell techniques

Official title: Evolution of Immune System in Healthy Adults After Vaccination of New Coronavirus (COVID-2019) Inactivated Vaccine Based on Single Cell Multi-Omics Technologies

Run by RenJi Hospital · NCT04871932 · Data updated 2026-11-12

This study is testing how healthy adults' immune systems respond to the COVID-19 vaccine using advanced techniques to better understand the different types of immune cells involved.

Quick facts

Study typeObservational
Ages18 Years to 50 Years
SexAll
Enrollment50 (estimated)
SponsorRenJi Hospital
Academic / other
Locations1 site (Shanghai)
StatusRecruiting
StartedFebruary 1, 2021
Main results expectedNovember 3, 2026
Study endsDecember 3, 2026
Registry record updatedJune 3, 2021
Trial IDNCT04871932 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are healthy adults aged 18 to 50 with no significant medical history or current infections.

Probably not a fit

Patients with infectious diseases, autoimmune disorders, or a history of major health issues may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to recruit healthy adults aged 18 to 50 to analyze the immune response to COVID-2019 vaccination through advanced single-cell multi-omics techniques. By utilizing single-cell RNA sequencing, the study will classify peripheral blood mononuclear cells (PBMCs) to gain insights into immune cell heterogeneity and functionality. The research focuses on understanding the variations in immune cell populations and their potential implications for disease-related research. The findings could enhance our understanding of the immune system's response to vaccination.

Why it matters

Potential benefit: If successful, this study could provide valuable insights into the immune response to COVID-2019 vaccination, potentially leading to improved vaccine strategies.

How similar studies have gone: Other studies utilizing single-cell sequencing have shown promise in understanding immune responses, indicating that this approach is both relevant and potentially impactful.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1\. Age from 18 to 50 years; 2. No history of major diseases, no history of bacterial or viral infection in the past 3 months; 3. No recent history of surgery or trauma; 4 No history of smoking or alcoholism; 5. No immune system disease.

Exclusion Criteria:

1\. Infectious diseases; 2. Tumor diseases; 3. Hematological diseases; 4. History of hypertension and diabetes; 5 Autoimmune diseases; 6 History of liver and kidney insufficiency; 7. History of previous cardiovascular diseases; 8. Pregnancy Or breast-feeding; 9. Past and current use of immunosuppressive drugs

Where it's running

  • Cardiology, Ren Ji Hospital
    Shanghai, China
    Recruiting

Study contacts

  • Principal investigator: Jun Pu, MD,PhD — Cardiology, Ren Ji Hospital Shanghai, China
  • Study coordinator: Jun Pu, MD,PhD
  • Email: pujun310@hotmail.com
  • Phone: 86-21-68383477

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.